Income Statement
LEXEO THERAPEUTICS, INC.
LXEO
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
- | - | - |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
- | - | - |
|
Operating Expenses
|
109.26 | 105.77 | 68.51 |
|
Research & Development
|
63.80 | 74.09 | 53.13 |
|
Selling, General & Administrative
|
45.46 | 31.68 | 15.38 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-109.26 | -105.77 | -68.51 |
|
Non-Operating Income
|
9.30 | 7.43 | 2.12 |
|
Interest Income
|
6.13 | 7.56 | 2.87 |
|
Interest Expense
|
- | - | 0.21 |
|
Other Non-Op Income / Expense
|
-0.02 | -0.01 | -0.01 |
|
Income Before Tax
|
-99.67 | -98.33 | -66.39 |
|
Income Tax Expense
|
0.00 | 0.00 | 0.00 |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-99.96 | -98.33 | -66.39 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-108.99 | -105.46 | -68.24 |
|
Earnings Per Share (Basic)
|
-1.86 | -3.09 | -12.40 |
|
Diluted EPS
|
-1.86 | -3.09 | -12.40 |
|
Weighted Average Shares
|
53.65 | 31.79 | 5.35 |
|
Diluted Weighted Avg Shares
|
53.65 | 31.79 | 5.35 |
|
Comprehensive Income
|
-99.67 | -98.44 | - |